CMA

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Retrieved on: 
월요일, 3월 11, 2024

The sNDA is based on 2-year confirmatory results from the Phase 3 PROTECT Study, the only head-to-head study in IgAN versus an active comparator.

Key Points: 
  • The sNDA is based on 2-year confirmatory results from the Phase 3 PROTECT Study, the only head-to-head study in IgAN versus an active comparator.
  • “Since being introduced under accelerated approval, FILSPARI has positively impacted the lives of many people living with IgAN.
  • “FILSPARI is at the forefront of emerging new treatment options providing hope for a delay in kidney transplant or dialysis.
  • The FDA has 60 days from the receipt of the application to determine whether to accept it for review.

Global Water Resources Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
목요일, 3월 7, 2024

PHOENIX, March 06, 2024 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • PHOENIX, March 06, 2024 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the fourth quarter and full year ended December 31, 2023.
  • Water consumption increased 19.4% to 0.90 billion gallons in the fourth quarter of 2023.
  • Recycled water volume increased 12.6% to 818 million gallons in the fourth quarter of 2023.
  • Global Water Resources will hold a conference call tomorrow to discuss its fourth quarter and full year 2023 results, including a question-and-answer period.

Montreal Resale Market Turns Around Earlier Than Anticipated

Retrieved on: 
수요일, 3월 6, 2024

L’ÎLE-DES-SOEURS, Quebec, March 06, 2024 (GLOBE NEWSWIRE) -- The Quebec Professional Association of Real Estate Brokers (QPAREB) has just released its residential real estate market statistics for the month of February 2024. The most recent market statistics for the Montreal Census Metropolitan Area (CMA) are based on the real estate brokers’ Centris provincial database.

Key Points: 
  • Prices steadily climbing while market conditions continue to favour sellers despite an 18 per cent increase in total listings.
  • The most recent market statistics for the Montreal Census Metropolitan Area (CMA) are based on the real estate brokers’ Centris provincial database.
  • The median price increases were more pronounced for Vaudreuil-Soulanges (+11 per cent) and the South Shore of Montreal (+9 per cent).
  • The Island of Montreal, Laval, the North Shore of Montreal and Saint-Jean-sur-Richelieu follow with a similar increase of 5 per cent.

An Early Spring for Quebec City: Sales and Prices Are Up in February

Retrieved on: 
수요일, 3월 6, 2024

The most recent market statistics for the Quebec City Census Metropolitan Area (CMA) are based on the real estate brokers’ Centris provincial database.

Key Points: 
  • The most recent market statistics for the Quebec City Census Metropolitan Area (CMA) are based on the real estate brokers’ Centris provincial database.
  • Residential sales in the Quebec City CMA territory totalled 967 in February 2024.
  • The South Shore of Quebec City (190 sales) follows with a significant increase of 19 per cent.
  • The median price of single-family homes in Quebec City’s Northern Periphery reached $377,000, up sharply by 14 per cent.

GXO Announces Offer to Acquire Wincanton

Retrieved on: 
목요일, 2월 29, 2024

Under the terms of the offer, each Wincanton shareholder will be entitled to receive 605 pence in cash for each Wincanton share held.

Key Points: 
  • Under the terms of the offer, each Wincanton shareholder will be entitled to receive 605 pence in cash for each Wincanton share held.
  • GXO has received irrevocable undertakings to accept (or to procure the acceptance of) the offer in respect of, in aggregate, 42,395,691 Wincanton shares and representing approximately 34.0% of the issued share capital of Wincanton as at 29 February 2024.
  • The irrevocable undertakings will cease to be binding in certain situations, including where a third party announces a competing offer where the value of the consideration is more than 695 pence per Wincanton share.
  • Wincanton customers will have the opportunity to seamlessly globalize their supply chain operations across the 27 countries where GXO operates.

OSS to Hold Fourth Quarter and Full Year 2023 Conference Call on Thursday, March 21, 2024 at 5:00 p.m. ET

Retrieved on: 
목요일, 2월 29, 2024

The financial results will be issued in a press release prior to the call.

Key Points: 
  • The financial results will be issued in a press release prior to the call.
  • OSS management will host the call followed by a question and answer period.
  • OSS regularly uses its website to disclose material and non-material information to investors, customers, employees and others interested in the company.
  • A replay of the call will be available after 8:00 p.m. Eastern time on the same day and through April 4, 2024.

Ladybug Resource Group Inc. Announces the Addition of a Chief Financial Officer and New Director

Retrieved on: 
수요일, 2월 28, 2024

TULSA, OK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ladybug Resource Group, Inc. (OTC PINK: LBRG) ("Ladybug" or the "Company") is delighted to announce that Bilal Bhamji has joined our company as Chief Financial Officer (CFO), and James Kurko has come on board as a Director.

Key Points: 
  • TULSA, OK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ladybug Resource Group, Inc. (OTC PINK: LBRG) ("Ladybug" or the "Company") is delighted to announce that Bilal Bhamji has joined our company as Chief Financial Officer (CFO), and James Kurko has come on board as a Director.
  • His current role as CFO at Tajiri Resources, a publicly traded company, further underscores his proficiency and strategic insight.
  • With a proven track record in the private and public sectors, Mr. Bhamji adds seasoned leadership to our team.
  • We are a forward-thinking entity in the health and wellness sector, operating under the name Ladybug Resource Group Inc., and doing business as Ladybug NutraTech.

High Wire Networks to Present at the 36th Annual ROTH Conference, March 18-19, 2024

Retrieved on: 
화요일, 2월 27, 2024

On March 18-19, High Wire CEO, Mark Porter, will participate in one-on-one meetings with analysts and investors.

Key Points: 
  • On March 18-19, High Wire CEO, Mark Porter, will participate in one-on-one meetings with analysts and investors.
  • High Wire was recently named to CRN’s MSP 500 and Elite 150 lists of the nation’s top IT managed service providers for 2024.
  • To schedule a one-on-one meeting with High Wire, please contact your ROTH representative.
  • For questions or further information about High Wire, please contact Ron Both of CMA at (949) 432-7557 or submit your request here .

Global Water Resources to Present at the 36th Annual ROTH Conference, March 17-19, 2024

Retrieved on: 
월요일, 2월 26, 2024

PHOENIX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has been invited to present at the 36th Annual ROTH Conference being held at The Ritz Carlton in Dana Point, California on March 17-19, 2024.

Key Points: 
  • PHOENIX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has been invited to present at the 36th Annual ROTH Conference being held at The Ritz Carlton in Dana Point, California on March 17-19, 2024.
  • On March 18-19, Global Water Resources CFO, Mike Liebman, will participate in one-on-one meetings with analysts and investors.
  • To schedule a one-on-one meeting with Global Water, please contact your ROTH representative.
  • For questions or further information about Global Water, please contact Ron Both of CMA at (949) 432-7557 or submit your request here .

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Retrieved on: 
금요일, 2월 23, 2024

SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). IgAN is a rare kidney disease and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission’s final decision regarding CMA for sparsentan. If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.

Key Points: 
  • The CHMP opinion provides the basis for the European Commission’s final decision regarding CMA for sparsentan.
  • If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.
  • In August 2022, Travere Therapeutics and CSL Vifor announced they had submitted a Marketing Authorization Application (MAA) for CMA to the EMA.
  • In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand.